Amyris Inc
F:3A01
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Amyris Inc
Current Portion of Long-Term Debt
Amyris Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Amyris Inc
F:3A01
|
Current Portion of Long-Term Debt
$120.8m
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Sherwin-Williams Co
NYSE:SHW
|
Current Portion of Long-Term Debt
$350.8m
|
CAGR 3-Years
605%
|
CAGR 5-Years
70%
|
CAGR 10-Years
61%
|
|
|
Dupont De Nemours Inc
NYSE:DD
|
Current Portion of Long-Term Debt
$60m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
127%
|
CAGR 10-Years
N/A
|
|
|
Ecolab Inc
NYSE:ECL
|
Current Portion of Long-Term Debt
$759.4m
|
CAGR 3-Years
15%
|
CAGR 5-Years
228%
|
CAGR 10-Years
-7%
|
|
|
PPG Industries Inc
NYSE:PPG
|
Current Portion of Long-Term Debt
$702m
|
CAGR 3-Years
32%
|
CAGR 5-Years
32%
|
CAGR 10-Years
10%
|
|
|
Albemarle Corp
NYSE:ALB
|
Current Portion of Long-Term Debt
$74.1m
|
CAGR 3-Years
233%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-20%
|
|
Amyris Inc
Glance View
Amyris, Inc. engages in the provision of bioscience solutions. The company is headquartered in Emeryville, California and currently employs 980 full-time employees. The company went IPO on 2010-09-28. The firm applies its Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products using its computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The firm's biotechnology platform enables users to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that it manufactures at industrial scale. Through the combination of its biotechnology platform and industrial fermentation process, the Company has developed, produced, and commercialized many distinct molecules. The firm is focused on three market areas, Health & Wellness, Clean Beauty and Flavor & Fragrance. Its brands include Biofene, Hemisqualane, Biossance, clean beauty skincare, Pipette, clean baby skincare and Purecane.
See Also
What is Amyris Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
120.8m
USD
Based on the financial report for Dec 31, 2022, Amyris Inc's Current Portion of Long-Term Debt amounts to 120.8m USD.
What is Amyris Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
16%
Over the last year, the Current Portion of Long-Term Debt growth was 11%. The average annual Current Portion of Long-Term Debt growth rates for Amyris Inc have been 19% over the past three years , 16% over the past five years .
